Accuray Incorporated (ARAY) reported quarterly earnings results on Wednesday, Aug-17-2016. The company reported $-0.09 earnings per share for the quarter, missing the analyst consensus estimate by $-0.02. Analysts had a consensus of $-0.07. The company posted revenue of $95.00 million in the period, compared to analysts expectations of $99.46 million. The company’s revenue was down -6.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.07 EPS.
Accuray Incorporated opened for trading at $5.43 and hit $5.59 on the upside on Monday, eventually ending the session at $5.51, with a gain of 1.10% or 0.06 points. The heightened volatility saw the trading volume jump to 3,81,324 shares. Company has a market cap of $446 M.
In a different news, on Nov 9, 2015, Joshua Levine (CEO) purchased 50,000 shares at $7.12 per share price. According to the SEC, on Sep 1, 2015, Alaleh Nouri (SVP, General Counsel &) sold 957 shares at $6.80 per share price.
Accuray Incorporated is a radiation oncology company. The Company develops manufactures sells and supports treatment solutions. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. Its technologies the CyberKnife and TomoTherapy Systems are designed to deliver treatments including radiosurgery stereotactic body radiation therapy intensity modulated radiation therapy image guided radiation therapy and adaptive radiation therapy. Its principal radiosurgery products the CyberKnife Systems are robotic full-body radiosurgery system designed to treat tumors anywhere in the body non-invasively which include the CyberKnife M6 Series with configuration options of fixed collimators plus iris variable aperture collimator fixed collimators plus the InCise MLC and fixed collimators plus iris variable aperture collimator and the InCise MLC. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH TomoHD and TomoHDA.